Overview

Global Blood Therapeutics develops and delivers treatments for sickle cell disease. Its core product, Oxbryta (voxelotor), is an oral medicine approved by the FDA for SCD patients as young as 4 years old, and the company conducts research, clinical trials, and regulatory work to bring new therapies to market. Oxbryta works by acting on hemoglobin to reduce red blood cell sickling, supporting healthier blood flow. The company differentiates itself through a focused, disease-specific portfolio and active patient advocacy, prioritizing SCD care and community engagement alongside its R&D efforts. Its goal is to change the treatment paradigm for SCD by expanding options, improving outcomes, and progressing toward additional therapies for patients and families affected by the disease.